Ukachi N Emeruwa1, Chloe Zera2. 1. Department of Obstetrics and Gynecology, Brigham and Women's Hospital, 75 Francis Street, ASB 1-3, Boston, MA, 02115, USA. uemeruwa@partners.org. 2. Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA, 02215, USA.
Abstract
PURPOSE OF REVIEW: To elaborate on the risks and benefits associated with antenatal fetal surveillance for stillbirth prevention in women with diabetes. RECENT FINDINGS: Women with pregestational diabetes have a 3- to 5-fold increased odds of stillbirth compared to women without diabetes. The stillbirth risk in women with gestational diabetes (GDM) is more controversial; while recent data suggest the odds for stillbirth are approximately 50% higher in women with GDM at term (37 weeks and beyond) than in those without GDM, it is unclear if this risk is seen in women with optimal glycemic control. Current professional society guidelines are broad with respect to fetal testing strategies and delivery timing in women with diabetes. The data supporting strategies to reduce the risk of stillbirth in women with diabetes are limited. Antepartum fetal surveillance should be performed to reduce stillbirth rates; however, the optimal test, frequency of testing, and delivery timing are not yet clear. Future studies of obstetric management for women with diabetes should consider not just individual but also system level costs and benefits associated with antenatal surveillance.
PURPOSE OF REVIEW: To elaborate on the risks and benefits associated with antenatal fetal surveillance for stillbirth prevention in women with diabetes. RECENT FINDINGS:Women with pregestational diabetes have a 3- to 5-fold increased odds of stillbirth compared to women without diabetes. The stillbirth risk in women with gestational diabetes (GDM) is more controversial; while recent data suggest the odds for stillbirth are approximately 50% higher in women with GDM at term (37 weeks and beyond) than in those without GDM, it is unclear if this risk is seen in women with optimal glycemic control. Current professional society guidelines are broad with respect to fetal testing strategies and delivery timing in women with diabetes. The data supporting strategies to reduce the risk of stillbirth in women with diabetes are limited. Antepartum fetal surveillance should be performed to reduce stillbirth rates; however, the optimal test, frequency of testing, and delivery timing are not yet clear. Future studies of obstetric management for women with diabetes should consider not just individual but also system level costs and benefits associated with antenatal surveillance.
Authors: Lorna E Thorpe; Diana Berger; Jennifer A Ellis; Vani R Bettegowda; Gina Brown; Thomas Matte; Mary Bassett; Thomas R Frieden Journal: Am J Public Health Date: 2005-07-28 Impact factor: 9.308
Authors: M I Schmidt; B B Duncan; A J Reichelt; L Branchtein; M C Matos; A Costa e Forti; E R Spichler; J M Pousada; M M Teixeira; T Yamashita Journal: Diabetes Care Date: 2001-07 Impact factor: 19.112
Authors: Aaron B Caughey; Vandana Sundaram; Anjali J Kaimal; Yvonne W Cheng; Allison Gienger; Sarah E Little; Jason F Lee; Luchin Wong; Brian L Shaffer; Susan H Tran; Amy Padula; Kathryn M McDonald; Elisa F Long; Douglas K Owens; Dena M Bravata Journal: Evid Rep Technol Assess (Full Rep) Date: 2009-03
Authors: Brenda Niu; Vanessa R Lee; Yvonne W Cheng; Antonio E Frias; James M Nicholson; Aaron B Caughey Journal: Am J Obstet Gynecol Date: 2014-06-06 Impact factor: 8.661
Authors: Blair G Darney; Jonathan M Snowden; Yvonne W Cheng; Lorie Jacob; James M Nicholson; Anjali Kaimal; Sascha Dublin; Darios Getahun; Aaron B Caughey Journal: Obstet Gynecol Date: 2013-10 Impact factor: 7.661
Authors: Amanda S Trudell; Methodius G Tuuli; Graham A Colditz; George A Macones; Anthony O Odibo Journal: PLoS One Date: 2017-03-07 Impact factor: 3.240